middle.news
How Clarity’s Cu-SAR-bisPSMA Trial Could Transform Prostate Cancer Detection
9:10am on Tuesday 10th of March, 2026 AEDT
•
Healthcare
Read Story
How Clarity’s Cu-SAR-bisPSMA Trial Could Transform Prostate Cancer Detection
9:10am on Tuesday 10th of March, 2026 AEDT
Key Points
Phase III AMPLIFY trial enrolment target exceeded
Trial conducted across US and Australia with 220+ participants
Cu-SAR-bisPSMA shows improved detection over current standard-of-care
Complementary Phase III CLARIFY trial ongoing
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLARITY PHARMACEUTICALS (ASX:CU6)
OPEN ARTICLE